Mapping Pathways is a multi-national project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral-based prevention strategies to end the HIV/AIDS epidemic. The evidence base is more than results from clinical trials - it must include stakeholder and community perspectives as well.

Showing posts with label circumcision. Show all posts
Showing posts with label circumcision. Show all posts

02 August 2012

Changing the way HIV prevention is delivered – a roadmap

via aidsmap, by Roger Pebody

In the last few years there has been a wealth of dramatic data on the efficacy of new HIV prevention methods, including male circumcision, pre-exposure prophylaxis and treatment as prevention. While last week’s 19th International AIDS Conference (AIDS 2012) didn’t deliver similar headline-grabbing studies, there were important discussions about how policy makers can implement effective HIV prevention strategies.

“We need to start thinking about the populations who are most at risk for targeted interventions,” Nelly Mugo of the University of Nairobi told a plenary session. “Then we will need to prioritize those interventions that work within those populations, and deliver them in combination with high coverage for us to get high impact.”

Speakers at other sessions gave numerous examples of the choices and dilemmas involved at each stage, drawing upon experience in the United States and in African countries.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

13 July 2012

An AIDS-Free Generation?

via Science, by Salim S. Abdool Karim

The HIV pandemic remains a great global health challenge.  With an estimated 3.3 million people living with HIV today, is there really hope of achieving the vision of an AIDS-free generation? Optimists argue that strong political will and generous funding are the essential elements. But skeptics point to the deep-seated structural inadequacies in many health care systems, especially in Africa, where the need is greatest.

However, both sides agree that a potential combination of therapeutic and prophylactic antiretroviral strategies brings the prospect of HIV control within reach. And this month, the International AIDS Conference in Washington, DC, “Turning the Tide Together,” will attempt to galvanize concerted global action to focus the world’s attention on this challenge.

Knowledge of HIV status is the common gateway to both treatment and prevention. But many people remain unaware of their HIV status. Denial, stigma, and a lack of understanding of vulnerability and risk lead to low rates of HIV testing, suboptimal condom use, and poor rates of circumcision. In addition to wider HIV testing, scale-up of ART therapy, both for the patient’s benefit and for the prevention benefi t to partners,will be key to reducing HIV transmission and to reaching zero new HIV infections.

Read the rest.

(This article requires you to sign up for a free registration to access to the full text)


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

23 March 2012

Protecting the Future: In conversation with Dr. Melissa Wallace

Original content from the Mapping Pathways blog team



Dr. Melissa Wallace is the Adolescent Project Leader at the Desmond Tutu HIV Foundation (DTHF) in South Africa. She is trained as a health psychologist and has been working in the field of HIV.

MP: How did you get involved in the field of adolescents and HIV prevention and treatment?

MW:My PhD in the U.K was on the topic of cancer and the physical changes that result from cancer treatment – hair loss, amputation and scarring – and how people come to terms with these changes.  On reading the literature, I realized there was very little that had been done with adolescents who were dealing with these changes, which was strange considering that adolescence is a period in life when people are most aware of their appearance and their bodies. So it was that decision to focus on adolescents during my PhD that led me on this road. After returning to South Africa, I realized that the biggest health problem facing us was HIV, and adolescents as a group were contributing a lot to the epidemic. This made me keen to work in this field.

MP: What is the reason behind DTHF’s focus on adolescents?

MW:In South Africa, we have a generalized HIVepidemic. However, there are some sub groups more at risk for HIV acquisition and adolescents are one of the groups most at risk.This is something that the DTHF has recognized for some time. If you look at graphs of HIV incidence for adolescent boys and girls – they reach the age of about 14-15 and suddenly the graphs become steep as incidence rises, and this is particularly the case for adolescent girls.  The fact is that they are often in relationships where they have very little control. There is also high gender inequality, poverty and less access to health services. All these factors play a role in putting adolescents at a high risk.

Also adolescence, in general, is a difficult time in one’s life. It’s a time where people are trying to find their identity, are curious, and have a higher chance of indulging in risky behavior. This may be sexually risky behavior or willingness to indulge in substance abuse. This is an age when kids break away from their parents more and peers become more of an influence. This makes them more likely to take risks in general.

In South Africa, there are also a lot of contextual factors that drive this epidemic for adolescents, particularly girls. For instance, there’s a lot of trans generational sex: girls having sex with much older male partners who are much more likely to be exposed to HIV already. There’s also a lot of transactional sex – girls and boys who will have sex for goods or money. Meaning that even though these youngsters may not be sex workers, there is a financial incentive for them to have sex. This is exacerbated by poverty.

MP: What are your current projects on the topic of adolescents and HIV prevention?

MW:We are working on a number of projects, including a follow-up study to a big three-year study that looked at building capacity for conducting vaccine trials among adolescents in South Africa. We recognized that there might be several biomedical prevention interventions at varying stages of development that could be licensed for use and unless we run trials with adolescents and build capacity, they wouldn’t be licensed for use with them. We also recognized that any prevention interventions targeting adolescents in particular would be best implemented prior to sexual debut. 

We developed six sites around South Africa and implemented adolescent friendly sexual health services at these sites. We also thought in detail about ethical and legal issues involved in conducting trials with adolescents, such as whether they could be recruited and whether parents would allow them to take part in this study. We did this by running a ‘mock’ HIV vaccine trial, using the (already licensed) HPV vaccine as our product. This gave us the opportunity to explore a number of key feasibility, ethico-legal and socio-behavioural questions.

Another study we’re hoping to start in the next couple of months is the FACTS 002 trial – which is an offshoot to the FACTS 001 trial (FACTS 001 is looking at the efficacy of tenofovir gel in adult women). FACTS 002 will be different in that it will address the safety and acceptability of tenofovir gel in girls who are a bit younger; participants’ age would range from 16-17 years old. The study will also address issues of adherence to the gel and how adolescents would feel about using it.

Another exciting project in its early stages is an MP3 project (methods of prevention) awarded to us by the NIH (National Institutes of Health). This project looks at feasibility and acceptability of a number of prevention methods that may become available in the future to adolescents. With all the progress with ARV based prevention methods, we envisage there may be a whole range of options available to people – and adolescents - to protect themselves from HIV. We’ll be running individual pilot studies on PrEP, microbicides and medical male circumcision and looking at issues around acceptability and feasibility and adherence. Finally, we will conduct a study in which we introduce a range of prevention options to adolescents and find out why and how they would make decisions about preferred prevention strategies, and what factors are important to them in making these decisions. This is a project we are really excited about since there’s not much that’s been done in this area with this age group.

FACTS 001 and the MP3 project will both take place at our brand new Youth Centre in the township of Masiphumelele. The Youth Centre itself has adopted a philosophy that we are hoping will contribute to a comprehensive prevention strategy for adolescents.  The Centre provides recreation services, education services and a reproductive health clinic together under one roof, for young people between the ages of 12 and 22. Our goal is to provide a safe, non-judgemental environment where young people can develop skills, learn and have fun, and enjoy a supportive environment where they are equipped to make the healthy choice in all aspects of their lives, including those issues related to HIV.

MP: What is the hardest part of your job?

MW:Sometimes the enormity of the problem feels overwhelming.  HIV is such a vast problem in South Africa and some of the structural factors – gender, equality, stigma and poverty make it that much harder to overcome. Sometimes, no matter what one does, the socio-economic circumstances are hard to get around. But I feel that we are at least doing something positive and impactful. There’s also a constant need to find funding to continue what we do and it is sometimes a challenge to be chasing that all the time to try and continue the work that we’re doing.

MP: Why does this work matter? Why does it excite you? 

MW: This work matters because, as a group,adolescents in South Africa are the most at risk for HIV, and we have a big opportunity to change the course of this epidemic if we target this group. Creating an impact prior to sexual debut will have the biggest positive impact on fighting this epidemic in the long term. 

This is a group that has been overlooked in healthcare a lot, partly since people see adolescents as harder to work with, so while there is established pediatric and adult care, adolescents are not afforded the same specialized care, something which is badly needed. There are also a number of other perceived challenges that come with working with this group. For instance, there are legal issues around conducting research and providing services to young people, as well as additional challenges like confidentiality and parental consent. To help deal with these issues, we have drafted a set of guidelines: Who gets the results from an HIV prevention study? Where does our responsibility lie: if we hear of something disturbing, do we notify the parents or higher authorities? These are the kinds of questions the guidelines seek to cover.

And finally and most importantly, at the risk of sounding cheesy, taking care of these adolescents is like taking care of the future of our country. Adolescents will grow up to be the adultsin our society, so whatever we can do now to protect their future is important.Particularly within the South African context, considering the poor socio-economic circumstances, these kids may feel that they don’t have a future worth staying HIV negative for–but it is our job to convince them otherwise andto make them feel excited and positive about their lives. This may be the key in helping them want to protect their HIV-negative status.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

06 January 2012

Shifting medical male circumcision to non-physician clinicians in Africa possible

via Aidsmap, by Carole Leach-Lemens

With proper training and supervision task shifting of medical male circumcision to non-physician clinicians in Africa can be done safely, according to researchers in South Africa and North America reporting in the advance online edition of AIDS.

This systematic review and analysis of ten studies (from South Africa, Kenya, Comoros, Nigeria, Zambian and Uganda) with information on over 25,000 circumcisions done by trained non-physician clinicians (nurses, midwives, surgical aides and clinical officers) found adverse events were not serious; and the pooled relative risk in two studies separately reporting outcomes for doctors and non-physicians showed comparable rates of adverse events (1.18: 95% CI: 0.78-1.78).

Evidence from randomised trials and observational studies support the protective effect of male circumcision for men getting HIV. Widespread male circumcision in Africa could prevent up to six million new infections and three million deaths in the next twenty years according to mathematical modelling estimates, note the authors.

With its potential as a high impact and cost-effective intervention both UNAIDS and the World Health Organization (WHO) promote voluntary male medical circumcision, with the latter providing guidelines for scaling-up of services in eastern and southern Africa.

In addition to ethical and acceptability challenges a severe shortage of health care workers in high prevalence countries, notably in Eastern and Southern Africa, is one of the major obstacles to effective scale-up.
Task shifting, the planned delegation of tasks from specialists or doctors to non-physician health care professionals, is a proposed strategy supported by WHO to increase scale-up of HIV treatment and prevention services. Randomised trials have provided evidence of the safety and efficacy of task shifting for ART.

To date evidence of the safety of circumcision by non-physician health care workers has been mixed. Reports of high rates of serious complications, note the authors, have confused those circumcisions undertaken by lay people with little or no training, lack of supervision or supportive equipment with circumcisions undertaken as a result of task shifting.

While there have been systematic reviews looking at the frequency of adverse events after circumcision, none have specifically looked at task shifting, note the authors.

The authors undertook a search of online databases and conference websites up to July 2011 reporting the outcomes of task shifting for circumcision in Africa.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

15 December 2011

HIV Researcher Dr. Robert Grant named Time "Person of the Year"

via Time, by Alice Park

People Who MatteredDr. Robert Grant has been a quietly powerful force in HIV research for years. In the early 2000s it was Grant, a professor of medicine at University of California, San Francisco, and Gladstone Institute of Virology and Immunology, who pushed to test the potential of antiviral drugs — normally used to treat people who already have HIV — as a way to protect healthy, uninfected people from acquiring the virus. His first study of the medications in gay men wasn't popular — why test the drugs in healthy people when millions of HIV-positive patients didn't even have access to the medications? — but proved successful, lowering new infection rates among men taking the antivirals prophylactically.

But it wasn't until 2011 that Grant's true influence on the battle against AIDS finally emerged. His initial research set the stage for further studies of the treatment-as-prevention strategy in other populations. This year a groundbreaking study found that treating the uninfected partner in heterosexual couples — in which one person had HIV and the other did not — dramatically reduced the risk of transmission. Another study found that giving antiviral drugs to heterosexual men and women also cut their risk of infection. The findings are crucial, since it is the heterosexual population that currently bear the heaviest burden of new HIV infections around the world. With hopes for a vaccine continually receding and safe-sex campaigns of limited value, Grant's idea (along with other emerging prevention strategies, like male circumcision) has the potential to halt the AIDS epidemic by stopping infections from occurring in the first place


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

12 December 2011

To End AIDS, We Need a Plan!

via Huffington Post, by Mitchell Warren

Last Thursday (December 1), on World AIDS Day, President Obama threw the full weight of the U.S. government behind a vision that would have seemed outlandish until now: The end of the global AIDS epidemic.

Over the past few years, a string of HIV prevention research breakthroughs has put that ambitious goal within sight for the first time. Voluntary medical male circumcision is the most powerful, under-utilized biomedical HIV prevention strategy available: with a single surgical procedure, men's risk of HIV from female partners is reduced by more than 60 percent. Treatment for HIV positive individuals is also potent prevention -- reducing risk of transmission by up to 96 percent.

These two strategies are the cornerstone of a new era of HIV prevention, and it is critical that the president continue to be a supporter and leader of the chorus of advocates, health and political leaders who are saying "Yes, we can end AIDS."

Now the question is: How will we achieve this goal? What are the priority actions to take today, tomorrow, and years from now?

First and foremost, the resource commitments need to match the strength of the scientific data. Funds are needed to ensure that the most effective prevention is put in place for the people who need it, in programs that meet their needs, with rigorous evaluation of impact so that no dollars are wasted.

President Obama's commitment to expand access to HIV treatment for two million more people by 2013 is a wonderful first step. But his call to the leaders of the world to match the US commitment must be heeded.

Last week, the Global Fund to Fight AIDS, Tuberculosis and Malaria - which supports HIV treatment programs in resource-poor countries along with PEPFAR - announced that it has been forced to curtail new grant-making until2014. The Fund pointed to a drop-off in contributions from governments in the face of the global economic crisis.

There's no question that economies are hurting. But global AIDS programs are among the smartest investments in history: they've saved countless lives and have shifted the course of the epidemic so that annual HIV infections are on a slow but steady decline. In most cases, these efforts represent a tiny share of donor countries' national budgets - for the U.S., it's well under one percent. It is precisely at this moment, when the potential dividends are greatest, that the world's modest AIDS investments should be sustained.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

05 December 2011

Medical Male Circumcison's Potential Yet to Emerge in Practice

via The Financial Times, by Andrew Jack

A mural promotes the benefits of circumcision at a clinic in KenyaTzameret Fuerst whips two plastic rings out of her handbag and prises them together around her forefinger with a black rubber band, simulating a simple way to carry out male circumcision that she hopes will soon be widely adopted across Africa.

“This is a safe, simple, non-surgical device that needs no anaesthetic and is scaleable in resource-limited settings, using nurses to carry out the procedure in tents in rural areas,” she says. “It’s virtually painless, completely bloodless and does not require a sterile setting.”

The PrePex device that her company Circ MedTech has developed is one of a growing number of experimental tools in search of a market that has the potential to help radically reduce HIV transmission.
But circumcision is also a practice that – despite the evidence – has yet to be adopted as much or as fast as experts had hoped.

Many years after observational studies indicated that circumcised cultures had lower HIV prevalence, progress remains extremely slow. In 2005, the results of the first carefully randomised controlled clinical trials in Orange Farm in South Africa demonstrated that sexual transmission was reduced by 60 per cent in men who were circumcised.

A recent estimate published by UNAids highlighted a jump in adult male circumcisions, especially in Kenya, South Africa and Zambia. But with 555,000 interventions in men aged 15-49 across sub-Saharan Africa by the end of last year, less than 3 per cent has been achieved of a target of 21m set for 2015 to reduce significantly new infections in the region.

“It’s going to be a big challenge to reach this target,” concedes Gottfried Hirnschall, head of the World Health Organization’s HIV programme.

International organisations have publicly endorsed the importance of circumcision, and a number of guidelines have been established, but the response so far has been haphazard and funding remains modest.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

02 December 2011

AVAC Realeases Its 2011 Report: "The End?"

via AVAC

This AVAC report presents a three-part agenda for ending the AIDS epidemic. It is intended as a vision and a challenge to the field, and a first step in holding all of us—civil society, researchers, governments, and funders—accountable for progress.

Each of the major priorities below demands action now—but the dividends will come in the short, medium, and long terms.

1. DELIVER today’s proven strategies at scale for immediate impact
  • Model combination prevention programs to identify the parameters that are essential for scale-up to have a major impact on infections
  • Mobilize demand for new tools among people who could benefit, through social marketing and other efforts
  • Reprogram existing resources when evidence shows they could be used to greater effect
  • Fund evidence-based scale-up today—and save money in the future—through substantial increases in commitments from U.S., European and developing country funders.
2. DEMONSTRATE and roll out newly available HIV prevention tools, including PrEP and microbicides, for even greater impact in 5 to 10 years
  • Plan for the introduction of PrEP and microbicides in the next several years, and for follow-on research needed to address questions that remain unresolved in trials to date
  • Pilot these interventions through demonstration projects that help define their optimal use and real-world impact
  • Prioritize the use of these interventions in populations, and in combinations, where the potential benefits are greatest
3. DEVELOP long-term solutions—including an effective vaccine and a cure—that will enable us to close the door on AIDS
  • Sustain funding for research, to capitalize on recent scientific insights that have begun to revitalize the search for a vaccine, while pursuing new leads that may eventually result in a functional cure for HIV infection.
Read the full report here.

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

16 September 2011

Male Circumcision and HIV Prevention

via Daily Monitor, by Moses Karugaba

In 2005, a randomised controlled trial conducted among uncircumcised men of 18-24 years in South Africa showed that male circumcision reduced the risk of acquiring HIV infection by 60 per cent. Two further studies conducted in Uganda and Kenya showed similar results. These three studies provide new, compelling evidence that male circumcision offers significant protection against acquiring HIV infection. These findings confirm those from previous observational studies and that of a meta-analysis of 28 published studies conducted in 2000.
What is Safe Male Circumcision (SMC)? Male circumcision involves the surgical removal of the foreskin, the tissue covering the head of the penis. In adult men, a four to six weeks period is required for the wound to heal fully compared to the one-week period when circumcision is performed for babies.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

14 September 2011

Fighting AIDS: At the Tipping Point


Starting in 2005, a series of randomized clinical trials demonstrated that medical male circumcision significantly reduces a man's risk of acquiring HIV. A recent follow-on study suggests the reduction in risk may be as much as 68% and the protective effect is increasing over time. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) is sponsoring large programs in countries where rates of HIV prevalence are high and levels of circumcision are low to bring this inexpensive and life-saving intervention to millions of men.

In May, a National Institutes of Health (NIH) randomized control trial documented for the first time that treatment also works as an extraordinarily successful tool for prevention. Initiation of antiretroviral treatment (ART) by HIV-positive individuals substantially protected their HIV-negative sexual partners from acquiring HIV. Treatment lowers the viral load of HIV in a person with the virus, greatly reducing the risk of sexual transmission to a partner. ART produced an astonishing 96 percent reduction in risk of HIV transmission, on par with a vaccine.

Earlier this summer, two other studies confirmed an initial proof-of-concept trial demonstrating the effectiveness of antiretroviral medication for pre-exposure prophylaxis (PrEP) among couples. Individuals taking a daily tenofovir or tenofovir/emtricitabine combination experienced infection rates as much as 73% lower than those on a placebo, advancing potential options for prevention among couples where one partner is infected with HIV and the other is not.

Finally, last summer, the CAPRISA study of tenofovir gel microbicide -- funded by PEPFAR through USAID -- found that those using the gel with the active ingredient had an average of 39% fewer HIV infections and 51% fewer genital herpes infections compared to women who used a placebo gel. These results provided the first evidence that an antiretroviral drug in a microbicide preparation can reduce the risk of HIV in women.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

22 July 2011

Sharing Patents to Wipe Out AIDS


Not since the announcement in 1996 that antiretroviral therapy could effectively control H.I.V. has there been a season of AIDS news as hopeful as this one.  Trials of a new microbicide have brought positive results; ongoing studies of circumcision are showing that it gives strong, lasting, protection; a man has been cured of H.I.V. infection and new animal and clinical trials are raising hopes that he won’t be alone.

The research with the most immediate and dramatic impact, however, examines two novel ways to use those antiretroviral drugs.  People with H.I.V. who start their antiretroviral therapy as soon as they are diagnosed, instead of waiting for their immune systems to degrade, have a near-zero chance of passing the virus on to their sexual partners. This is the AIDS vaccine we’ve been waiting for — a 96 percent drop in infection rates is far better protection than any actual AIDS vaccine could  provide.  It has also now been shown that giving one antiretroviral pill a day to people who don’t have H.I.V. but are at very high risk for catching it can reduce their risk by two-thirds or more.

Taken together, these two methods of using antiretroviral drugs not just to treat AIDS, but also to prevent its spread, offer real hope of ending the epidemic.  But there’s a catch:  they require providing these drugs to millions, perhaps tens of millions, more people than are getting them now.  Someone has to pay for all this.

That’s why it matters that last week, Gilead Sciences, one of the most important manufacturers of AIDS drugs, became the first drug maker to join something called the Medicines Patent Pool, a two-year-old organization that was established by Unitaid, an international body dedicated to buying AIDS drugs. In joining the patent pool, Gilead agrees to let generic pharmaceutical companies copy four of its drugs for sale at very low prices in poor countries.  Gilead will get a small royalty for every copy sold.

Read the rest here.

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

19 July 2011

Capitalizing on Scientific Progress

A report released this morning by HIV Vaccines and Microbicides Resource Tracking Working Group at the IAS conference in Rome "found that overall investment in HIV prevention R&D had actually increased, with the modest exception of a one percent decline in vaccine R&D. The report documented a total US$1.19 billion investment in research and development (R&D) for four key HIV prevention options: preventive vaccines, microbicides, pre-exposure prophylaxis (PrEP) using antiretroviral drugs, and operations research related to medical male circumcision.":

"2010 has been a year of retrospection, a time for looking back over the 30 years since the first published report of the mysterious illness that would come to be known as AIDS. As sobering as this anniversary has been, it has also been a time for some optimism and calls to end the epidemic. These calls may not be simply wishful thinking, fueled as they have been by promising research results over the past two years in vaccines, microbicides, pre-exposure prophylaxis using antiretrovirals (PrEP), and antiretroviral treatment as prevention—results that have energized the entire HIV prevention field.

The first good news came at the end of 2009, when researchers in the RV 144 Thai vaccine trial reported that a vaccine combination had reduced risk of infection by 31 percent—the first clinical evidence that a preventive AIDS vaccine would be possible. Then, in July 2010, the CAPRISA 004 trial team announced its findings–that use of 1% tenofovir (TDF, also known as Viread®) vaginal gel reduced women’s risk of HIV infection by 39 percent—providing the first proof that a microbicide would be possible. This news was followed in November 2010 by the announcement from the iPrEx trial team that daily oral tenofovir/emtricitabine (TDF/FTC, also known as Truvada®) had reduced risk of HIV infection by an estimated 44 percent overall in men who have sex with men (MSM) and transgender women, and proved for the first time that HIV prevention using PrEP would be possible. And finally, in early 2011, the HIV Prevention Trials Network (HPTN) 052 trial established that use of antiretroviral therapy (ART) by HIV-positive individuals reduced transmission to their partners"

Source: HIV Vaccines and Microbicides Resource Tracking Working Group

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]